

Canaccord Genuity's U.S. Investment Banking Team Completes 211 Transactions in the Last Twelve Months¹

112 Financial Advisory Deals and 99 Capital Markets Offerings¹

Selected Transactions Announced as of 3/31/22¹

 HRA Pharma \$2,100,000,000 Financial Advisor on sale to Pending	 TAILWIND \$1,575,000,000 Capital Markets Advisor on merger with March 2022	 terraboost Financial Advisor on investment from March 2022	 ascendis pharma \$500,000,000 Convert Co-Manager March 2022	 PIEDMONT \$113,750,000 Follow-On Co-Manager March 2022	 Power Financial Advisor on investment from March 2022	 INARI \$186,300,000 Follow-On Co-Manager March 2022	 Swell Financial Advisor on sale to March 2022
 Aytu \$7,575,000 Follow-On Bookrunner March 2022	 TILRAY \$400,000,000 ATM Offering Co-Agent March 2022	 TA DIGITAL Financial Advisor on sale to Omnicom Group March 2022	 Giving Block Financial Advisor on sale to March 2022	 coherent path Financial Advisor on sale to February 2022	 calyxt \$10,941,212 Follow-On Bookrunner February 2022	 M&M \$322,000,000 Financial Advisor on sale to February 2022	 Spectrum Brands \$425,000,000 Financial Advisor on acquisition of February 2022
 cg/Canaccord Genuity \$1,200,000,000 Financial Advisor on merger with February 2022	 Wolfspeed \$750,000,000 Convert Co-Manager January 2022	 orthosense \$160,000,000 Financial Advisor on sale to AVANOS January 2022	 Sports Entertainment Acquisition Corp LLC \$4,463,000,000 Capital Markets Advisor on merger with January 2022	 NMG NOUVEAU MONDE GRAPHITE \$75,000,000 ATM Offering Lead Agent January 2022	 Berlin Rosen Financial Advisor on investment from January 2022	 ARCIMOTO \$100,000,000 ATM Offering Sole Agent January 2022	 CLEVER \$50,000,000 ATM Offering Sole Agent January 2022
 PLUS THERAPEUTICS \$5,000,000 ATM Offering Sole Agent January 2022	 Apax Financial Advisor on acquisition of January 2022	 Intra-Cellular Therapies \$400,000,000 Follow-On Co-Manager January 2022	 docebo \$200,000,000 ATM Offering Lead Agent January 2022	 EVERYTHING Financial Advisor on sale to January 2022	 The Spur Group Financial Advisor on sale to January 2022	 acorn Financial Advisor on sale to January 2022	 SALES BOOMERANG Financial Advisor on investment from January 2022
 Glift \$50,000,000 Financial Advisor on investment from January 2022	 MASTERBUILT KAMADO JOE \$385,000,000 Financial Advisor on sale to December 2021	 MCAP ACQUISITION CORPORATION \$121,500,000 PIPE Transaction Joint Agent December 2021	 ROTHEORENT \$1,000,000,000 Financial Advisor on merger with December 2021	 energysage Financial Advisor on sale to December 2021	 Quartile Financial Advisor on acquisition of December 2021	 servicetrade \$85,000,000 Financial Advisor on investment from December 2021	 immunogen \$257,126,364 Follow-On Lead Manager December 2021
 Lithium Americas \$225,000,000 Convert Bookrunner December 2021	 WebFX Financial Advisor on investment from November 2021	 PRIVIA HEALTH \$174,000,000 Follow-On Bookrunner November 2021	 Rover \$60,000,000 Follow-On Co-Manager November 2021	 e-Emphasys Financial Advisor on investment from November 2021	 Hero Digital Financial Advisor on sale to November 2021	 Clover Health \$300,000,000 Follow-On Bookrunner November 2021	 DEFINITIVE HEALTHCARE \$396,000,000 Follow-On Co-Manager November 2021
 LANTRONIX \$40,537,500 Follow-On Bookrunner November 2021	 braze \$572,000,000 IPO Co-Manager November 2021	 Iris Energy \$231,538,468 IPO Bookrunner November 2021	 User Testing \$140,000,000 IPO Co-Manager November 2021	 mynaric \$66,000,000 IPO Bookrunner November 2021	 BENZINGA \$300,000,000 Financial Advisor on sale to October 2021	 COLEMAN \$103,350,000 Financial Advisor on sale to October 2021	 motion \$1,100,000,000 Capital Markets Advisor on merger with November 2021
 babylon \$4,200,000,000 Capital Markets Advisor on merger with Alkuri Global October 2021	 AGENTIS Financial Advisor on sale to October 2021	 Paragon \$125,000,000 IPO Lead Manager October 2021	 Bansk Financial Advisor on acquisition of September 2021	 DMD Financial Advisor on sale to August 2021	 bounteous Financial Advisor on investment from August 2021	 tinuiti Financial Advisor on acquisition of August 2021	 Prestige Consumer Healthcare Financial Advisor on acquisition of Consumer Health Segment July 2021

Ranked #1 for Middle Market TMT Deal Activity²

Rank	Firm Name	# of Transactions LTM 3/31/22	Rank	Firm Name	# of Transactions 2019-2021
1	Canaccord Genuity	68	1	Canaccord Genuity	127
2	William Blair	45	2	Raymond James	106
3	Raymond James	40	3	William Blair	87
4	Houlihan Lokey	35	4	Houlihan Lokey	71
5	Goldman Sachs	29	5	Baird	62
6	Baird	27	6	Goldman Sachs	53
7	Lincoln International	21	7	Evercore	45
8	Jefferies	19	8	Piper Sandler	43
9	Stifel	18	9	Stifel	39
10	Cowen	17	10	Jefferies	35
10	Harris Williams	17	10	Lincoln International	35
10	Piper Sandler	17	12	AGC Partners	34

Ranked #1 for Media & Information Services Deal Activity²

Rank	Firm Name	# of Transactions LTM 3/31/22	Rank	Firm Name	# of Transactions 2019-2021
1	Canaccord Genuity	40	1	Canaccord Genuity	76
2	Houlihan Lokey	21	2	Houlihan Lokey	37
3	Raymond James	14	3	Raymond James	32
4	GP Bullhound	10	4	Goldman Sachs	25
4	Goldman Sachs	10	5	Moelis	20
6	Moelis	9	6	Lincoln International	17
7	GCA	8	6	JEGI	17
7	KeyBanc	8	8	GCA	16
7	Lincoln International	8	9	Morgan Stanley	15
7	William Blair	8	9	William Blair	15

A Leading Investment Bank for U.S. Middle Market Healthcare Transactions ³

Rank	Firm Name	Deal Value (\$M)	# of Transactions
1	Piper Sandler	\$39,741	124
2	Canaccord Genuity	16,263	81
3	Stifel	16,884	80
4	William Blair	24,034	60
5	Cowen & Company	25,036	39
6	Raymond James	12,473	38
7	Oppenheimer	4,603	29
8	Robert W Baird	5,825	20
9	JMP Securities	1,793	15
10	Needham & Company	151	4

Leading Global Underwriter Supports M&A Activity – The Only Non Bulge-Bracket Bank in the Global Top 10⁴

Bank	Total Roles			Lead Manager		Co-Manager	
	Rank	Total Value (\$M)	No.	Rank	No.	Rank	No.
Goldman Sachs	1	1,309,611.1	1,889	1	1,855	85	34
JPMorgan	2	1,179,718.1	1,874	2	1,832	77	42
Morgan Stanley	3	1,206,698.8	1,829	3	1,771	57	58
BofA Securities	4	1,084,561.9	1,567	4	1,512	61	55
Citi	5	988,984.3	1,469	5	1,415	63	54
Canaccord Genuity	6	148,009.0	1,441	6	1,079	1	362
Credit Suisse	7	642,239.8	1,085	7	1,039	73	46
UBS	8	526,504.2	879	9	845	85	34
Stifel	9	257,806.1	871	12	559	3	312
Jefferies	10	302,615.7	869	8	858	152	11

¹Transactions include 11 M&A transactions completed by Sawaya Partners (acquired by Canaccord Genuity 12/31/21)

²Source: PitchBook for the time period 1/1/19-3/31/22. Transaction totals represent U.S. M&A/Control Transactions, All Buyout Types, and Growth/Expansion sell-side transactions <\$500M in the Technology, Media & Telecommunications and Media & Information Services segments as classified by PitchBook

³Source: Dealogic data since 2010 for Middle-Market Healthcare transaction activity, as of 12/31/21

⁴Source: Dealogic 1/1/19- 4/4/22. Includes all IPO, FO, & CONV

Canaccord Genuity is a dominant, full-service investment bank serving growth companies in the middle market. We continue to evolve and expand our presence, and we recently announced the acquisition of Sawaya Partners, one of the leading and most active M&A advisors to notable clients in the Consumer sector. During the twelve months ended March 31, 2022, Canaccord Genuity's team remained very active, executing the following on behalf of over 200 clients:

- Completed 211 total transactions for 202 different corporate clients¹
- Closed 112 advisory engagements, which ranged from growth and minority investments to strategic sales, private equity recaps, and divestitures¹
- Announced 99 capital markets transactions, ranging from IPOs, Follow-Ons, ATMs, PIPE's and capital markets advisory on SPAC Business combinations
 - Acted as underwriter on 68 capital markets transactions, raising in excess of \$23.1 billion in cumulative proceeds for more than 60 different issuers
 - Book-ran 20 equity offerings and managed 12 "At-the-Market" programs
- Closed 22 transactions involving SPACs, including SPAC IPOs, PIPE's and also served as Capital Markets and Financial Advisor on SPAC business combinations

The U.S. investment banking team continues to leverage deep industry expertise across a broad banking universe in practices, including:

- TMMIS (Technology, Media, Marketing, and Information Services)
- Healthcare (Biotechnology, Biopharmaceuticals, Digital Health, IT, Services, Medical Technologies, Diagnostics, and Cannabis)
- Consumer (Health & Wellness, Home & Auto, Food & Beverage, and Emerging Brands)
- Sustainability (Building Technologies, Mobility, Renewables and Distributed Generation, Services, Smart Grid/Smart City, Circular Economy, Energy Storage, and AgTech and FoodTech)

Our firm's track record of success is recognized by the financial sponsor community – approximately half of the firm's engagements involve representing investor-backed companies. Additionally our in-depth industry coverage also continues to position Canaccord Genuity's U.S. investment banking team as the go-to advisor for founder and management-owned businesses.

Our U.S. investment banking team, with approximately 125 professionals in Boston, Charlotte, Chicago, Nashville, New York, and San Francisco, among other locations, is part of a global group that can be leveraged to bring resources to our clients. We welcome the opportunity to discuss your business and your strategic objectives.

Through its principal subsidiaries, Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional, and corporate clients through comprehensive investment solutions, brokerage services, and investment banking services. The Company has Wealth Management offices located in Canada, the UK, Guernsey, Jersey, the Isle of Man, and Australia. The international capital markets division operates in North America, the UK & Europe, Asia, Australia, and the Middle East. Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX.

This document is provided for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the securities discussed in this document may not be eligible for sale in some jurisdictions. This document is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. Investors should obtain advice based on their own individual circumstances before making an investment decision. This publication is intended for institutional client use only, not for further distribution.

To the fullest extent permitted by law, neither Canaccord Genuity, nor its affiliates nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained in this document.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information is available on request.

For US distribution only.

Copyright ©Canaccord Genuity LLC, 2022. Member FINRA/SIPC.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity, a division of Canaccord Genuity Group Inc., Canaccord Genuity Limited, and Canaccord Genuity LLC. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.

Canaccord Genuity U.S. Senior Investment Banking Team

Jeff Barlow
President
Boston
jbarlow@cgf.com

Sanjay Chadda
Co-Head US & Tech Banking
New York
schadda@cgf.com

Dan Coyne
Co-Head US Banking
Boston
dcoyne@cgf.com

Jen Pardi
Global Head of ECM
Boston
jpardi@cgf.com

Sector Leads

TMMIS

Andrew Pojani
Co-Head US Tech
Investment Banking
Boston
apojani@cgf.com

Consumer

Fuad Sawaya
Vice Chairman & Global Head
Consumer Investment Banking
New York
fsawaya@cgf.com

Jeff Kuhr
Co-Head of US Consumer
Investment Banking
New York
jkuhr@cgf.com

Slava Leykind
Co-Head of US Consumer
Investment Banking
New York
sleykind@cgf.com

Healthcare

Tom O'Connor
Co-Head of US Healthcare
Investment Banking
New York
toconnor@cgf.com

Eugene Rozelman
Co-Head of US Healthcare
Investment Banking
New York
erozelman@cgf.com

Matt Steere
Co-Head of US Healthcare
Investment Banking
San Francisco
msteere@cgf.com

M&A

David Istock
Managing Director
San Francisco
distock@cgf.com

Sponsor Coverage

Bryan Cummings
Managing Director
New York
bcummings@cgf.com

Isaiah Knouff
Managing Director
Nashville
iknouff@cgf.com

Amy LaBan, CFA
Managing Director
Chicago
alaban@cgf.com

Senior US Team

Dudley Baker
Managing Director
Nashville
rdbaker@cgf.com

Lisa McClure Byrnes
Managing Director
Boston
lbyrnes@cgf.com

Scott Card
Managing Director
Boston
scard@cgf.com

Robert (Tenny) Field
Managing Director
New York
rfield@cgf.com

Matthew Kratter
Managing Director
New York
mkratter@cgf.com

Morgan Ley
Managing Director
Boston
mley@cgf.com

Ben Lunka
Managing Director
Charlotte
blunka@cgf.com

Marc Marano
Managing Director
Boston
mmarano@cgf.com

Trevor Martin
Managing Director
Boston
tmartin@cgf.com

J.P. Michaud
Managing Director
Charlotte
jmichaud@cgf.com

Joshua Michaels
Managing Director
New York
jmichaels@cgf.com

Jason Partenza
Managing Director
New York
jpartenza@cgf.com

Michael Petsky
Managing Director
New York
mpetsky@cgf.com

Tom Pollard
Managing Director
San Francisco
tpollard@cgf.com

John Prunier
Managing Director
New York
jprunier@cgf.com

Seth Rosenfield
Managing Director
New York
srosenfield@cgf.com

John Stack
Managing Director
New York
jstack@cgf.com

Mark Young
Managing Director
Boston
myoung@cgf.com

Bernard Yuen
Managing Director
New York
byuen@cgf.com

Chris DiPietro
Director
Boston
cdipietro@cgf.com

Nicholas Enthoven
Director
New York
nenthoven@cgf.com

Christopher Heasman
Director
New York
cheasman@cgf.com

Matthew Kebel
Director
New York
mkebel@cgf.com

Anil Kuruganti
Director
New York
akuruganti@cgf.com

Mike Raffaniello
Director
New York
mraffaniello@cgf.com

Geoff Rhizor
Director
San Francisco
grhizor@cgf.com

Wesley Rossiter
Director
Boston
wrossiter@cgf.com

Lexia Schwartz
Director
New York
lschwartz@cgf.com

Greg Staton
Director
New York
gstaton@cgf.com

Theodora Townsend
Director
New York
thtownsend@cgf.com

Edin Trto
Director
New York
etrto@cgf.com

Clayton Young
Director
New York
cyoung@cgf.com